Scientific Program – Embryology

Friday, November 13 only

Friday, November 13

08:30-10:00 AI AND AUTOMATION IN IVF LABORATORY HALL B
Capsule A recent RCT by Illingworth et al et al (Nature Medicine 2024) was unable to demonstrate non-inferiority of a deep learning algorithm compared with standard morphology. Although no harm in using AI selection was proven, AI -based solutions need to demonstrate improvement in time, quality, and safety in IVF laboratory procedures, without compromising clinical outcomes, while reducing cost, before widespread adoption
Chairpersons Rita Vassena, Spain
08:30-09:00

0830
08:40
08:50

Debate: Does AI improve embryo selection in IVF

Pro: AI can improve embryo selection Giovanni Coticchio, Italy
Con: RCTs are lacking and without clear proofs, it should not be adopted Alessandro Bartolacci, Italy
Discussion
09:00-09:25

AI in sperm selection: difficult cases and proxy molecular markers
09:25-09:30 Discussion
09:30-0955

Automation in lab work in IVF – how far did we get? Do we still need an embryologist?
09:55-10:00 Discussion

 

10:00-10:30 Coffee break, visit the exhibition and e-poster viewing

 

10:30-12:00 VITRIFICATION HALL B
Capsule Shorter vitrification and warming protocols are becoming more common for embryos, while still lagging somewhat behind oocytes. New approaches are being considered that challenge our understanding of cryobiology, and new media are being developed to improve results.
Chairpersons
10:30-10:55

Shorter protocols of vitrification and warming for oocytes
10:55-11:00 Discussion
11:00-11:25

Do we have the ultimate vitrification/warming media? How can we improve them?
11:25-11:30 Discussion
11:30-11:55

Is direct warming of embryos the new revolution?
Rita Vassena, Spain
11:55-12:00 Discussion

 

12:00-12:05 Short break

 

12:05-12:30 PLENARY SESSION HALL A
Streamed to all halls
Capsule
Chairpersons
12:05-12:30

PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc)

 

12:35-13:35 Industry supported session – Hall A
Industry supported session – Hall B 

 

13:35-14:30 Lunch break, visit the exhibition and e-poster viewing

 

14:30-15:30 IVM AND IMMATURE OOCYTES HALL B
Capsule In vitro maturation has by now proven safe and effective on a per-oocyte basis, although clinical adoption seems to be lagging. The efficiency of controlled ovarian hyperstimulation however, clashes with the comfort of patients and the increase in cost of the procedure (drugs, anesthetic services, recovery time, etc..). Is there a place for true IVM in standard clinical practice?
Chairpersons Alessandro Bartolacci, Italy
08:30-09:10

08:30
08:40
08:50

Debate: This house believes that “true” IVM should be part of the toolkit of every clinic

Pro: IVM should be indicated for certain patients
Con: IVM cannot rival OHSs in cumulative efficiency and should not be proposed
Discussion
09:10-09:30

Is there a point in performing rescue IVM on denuded oocytes after ovarian stimulation?
09:30-09:35 Discussion
09:35-09:55

In vitro derived oocytes: from research to clinical application
09:55-10:00 Discussion

 

15:30-15:35 Short break

 

15:35-17:00 QUO VADIS PGT-A? HALL B
Capsule In spite of the clear results from 2 non-selection studies, some questions still persist in the PGT-A world. We are debating advances and limitations of this technology, and look at future developments in the field. PGT-P for polygenic is a controversial technique that uses scores to estimate embryos risk to develop adults diseases like diabetes to select those with lower risk
Chairpersons Giovanni Coticchio, Italy
15:35-16:05

15:35
15:45
15:55

Debate: Should we report mosaicism in PGT-A?

Yes, we should:
No, we should not:
Discussion
16:05-16:25

When PGT-M is needed, should we test also for aneuploidy
16:25-16:30 Discussion
16:30-16:55

PGT-P: The future of PGT or an unethical approach?
Shai Carmi, Israel
16:55-17:00 Discussion

 

17:00-17:20 Coffee break, visit the exhibition and e-poster viewing

  

17:20-18:30 AN EMBRYO IS AN EMBRYO IS AN EMBRYO? HALL B
Capsule From choosing the best day to transfer to the developmental potential of nonconventional fertilized oocytes, this session will challenge some long held beliefs and present new evidence for
Chairpersons Rita Vassena, Spain
17:20-17:40

1PN, 2.1PN, 3PN: When to rescue and when to discard?
17:40-18:00

Are embryos better nurtured in utero or in vitro? A comparison of day 3 vs day 5 transfer, including a cost-effectiveness perspective
Giovanni Coticchio, Italy
18:00-18:20

How to care for the embryo in challenging laboratory settings
18:20-18:30 Q&A

 

Skip to content